🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thank you for highlighting our work! ☕️ Nature Reviews Drug Discovery Rony Dahan IdoAmitLab nature.com/articles/d4157…

1/3 We are EXTREMELY proud of not just one, but TWO of Systems_Immunology_WIS Weizmann Institute department's members just being awarded the prestigious 2024 Rappaport Prize. Our founding member PI @Ymerbl has been awarded the 2024 Rappaport Prize for Biomedical…

🔥Congratulations Yuval for this outstanding achievement 🏆 We are very proud of you

Honored to receive the 2024 Rappaport Prize in Biomedical Sciences for the development of new cancer immunotherapies. A big thank you to my mentor and PI Rony Rony Dahan , Systems_Immunology_WIS Weizmann Institute for making my science dreams a reality.

We are proud to share our latest work, in collaboration with Amos Tanay lab, presenting a framework for in vivo tracking of CD8+ T cells' response to immunotherapy over time & at single-cell resolution, led by Oren Barboy and Akhiad Bercovich. nature.com/articles/s4301…. (1/19)

Welcome aboard Tanita!

Why human anti-CTLA-4 antibodies do not deplete intratumoral Tregs ? We show that FcyRIIB acts as a checkpoint restricting the Fc-dependent activity of human anti-CTLA-4 and other Treg-targeting antibodies in tumor. Rockefeller University Cancer Immunology Research aacrjournals.org/cancerimmunolr… (1/10)

Lab paper alert! Myc mRNA has a very short lifetime and can not be accumulated. Sharon Sharon Kagan Ben Tikva shows that the frequency of Myc expression (transcriptional bursts), rather than its amounts, dictates B cell positive selection in germinal centers over time. science.org/doi/10.1126/sc…

Congratulations to Yuval Shapir Itai (from the group of Dr. Rony Dahan) upon being awarded the 2024 Rappaport Prize for an outstanding doctoral student for excellence in the field of Biomedical Research

Huge congrats to Yuval, our immune-engagers champion, for this well-deserved recognition

Outstanding award presentation by Yuval Shapir Itai while receiving the EPHAR-EACPT Young Investigator Award in Translational Pharmacology. Congrats Yuval, we are very proud of you 👏🏻 🏆 EACPT Systems_Immunology_WIS Weizmann Institute

Excited to share that I’ve been awarded the EACPT-EPHAR Young Investigator Award in Translational Pharmacology, and the opportunity to present our work here in Rotterdam. Thank you to EACPT, Rony Dahan and our collaborators 🙌🏼

In tumors, T cells interact with neoantigens, but which targets do B cells recognize? Here, we discuss how self-reactive B cells emerge in tumors via the germinal center reaction. Philipp The tumor-driven antibody-mediated immune response in cancer sciencedirect.com/science/articl…

Hepatitis B Immunotherapy ! Brilliant study. Congrats Matteo and the team 🎉

Our protocol to characterize bispecific engagers #immunotherapy

Fascinated discovery! Congrats

Had a great time presenting our work and hearing about exciting new science at the 3rd ImmunoSensation - IFReC International School on Advanced Immunology in Japan. Thanks for the amazing opportunity 🙏🏼 Rony Dahan

Just published📢 Our new forum article on Fc-optimized checkpoint antibodies for cancer therapy. New to immunotherapy and antibody engineering? This one’s for you! Co-authored with Alan Korman. Trends in Molecular Medicine #CancerImmunotherapy #FcEngineering sciencedirect.com/science/articl…

Looking forward for this one! Thanks Natalie and Pierre for organizing this great meeting

Reprogramming macrophages remains one of the outstanding unsolved challenges in cancer immunotherapy. Huge congratulations to IdoAmitLab Fadi Sheban and the team for tackling this complex task and publishing this impactful study.